Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.

Fatty acids beyond their role as an endogenous energy source and storage are increasingly considered as signaling molecules regulating various physiological effects in metabolism and inflammation. Accordingly, the molecular targets involved in formation and physiological activities of fatty acids hold significant therapeutic potential. A number of these fatty acid targets are addressed by some of the oldest and most widely used drugs such as cyclooxygenase inhibiting NSAIDs, whereas others remain unexploited. Compounds orthosterically binding to proteins that endogenously bind fatty acids are considered as fatty acid mimetics. On the basis of their structural resemblance, fatty acid mimetics constitute a family of bioactive compounds showing specific binding thermodynamics and following similar pharmacokinetic mechanisms. This perspective systematically evaluates targets for fatty acid mimetics, investigates their common structural characteristics, and highlights demands in their discovery and design. In summary, fatty acid mimetics share particularly favorable characteristics justifying the conclusion that their therapeutic potential vastly outweighs the challenges in their design.

[1]  N. Sharma-Walia,et al.  Lipoxins: nature’s way to resolve inflammation , 2015, Journal of inflammation research.

[2]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[3]  Amiram Goldblum,et al.  Indexing molecules for their hERG liability. , 2013, European journal of medicinal chemistry.

[4]  M. Raizman,et al.  In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac , 2007, Journal of cataract and refractive surgery.

[5]  J. Peters,et al.  Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.

[6]  Anna L. Blobaum,et al.  Molecular Determinants for the Selective Inhibition of Cyclooxygenase-2 by Lumiracoxib* , 2007, Journal of Biological Chemistry.

[7]  Nicholas A Meanwell,et al.  Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. , 2016, Chemical research in toxicology.

[8]  D. Im Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. , 2012, Progress in lipid research.

[9]  Oliver Werz,et al.  Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.

[10]  Shenghua Shi,et al.  Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent , 2009, Proceedings of the National Academy of Sciences.

[11]  T. Willson,et al.  Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist. , 2011, Bioorganic & medicinal chemistry letters.

[12]  T. Velkov,et al.  Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay. , 2007, Chemistry & biology.

[13]  G. Schneider,et al.  Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo. , 2013, Journal of medicinal chemistry.

[14]  G. Eichele,et al.  International Union of Pharmacology. LX. Retinoic Acid Receptors , 2006, Pharmacological Reviews.

[15]  Noeris K. Salam,et al.  Novel PPAR‐gamma Agonists Identified from a Natural Product Library: A Virtual Screening, Induced‐Fit Docking and Biological Assay Study , 2007, Chemical biology & drug design.

[16]  L. Altucci,et al.  RAR and RXR modulation in cancer and metabolic disease , 2007, Nature Reviews Drug Discovery.

[17]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[18]  Sandra K. Wittmann,et al.  N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. , 2016, Journal of medicinal chemistry.

[19]  R. Keith,et al.  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles. , 1990, Journal of medicinal chemistry.

[20]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.

[21]  D. Huryn,et al.  Structure Property Relationships of Carboxylic Acid Isosteres , 2016, Journal of medicinal chemistry.

[22]  G. Schneider,et al.  Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator. , 2010, Bioorganic & medicinal chemistry letters.

[23]  J. Imig Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. , 2016, Advances in pharmacology.

[24]  Sandra K. Wittmann,et al.  Thermodynamic properties of leukotriene A4 hydrolase inhibitors. , 2016, Bioorganic & medicinal chemistry.

[25]  M. Malkowski,et al.  Investigating Substrate Promiscuity in Cyclooxygenase-2 , 2012, The Journal of Biological Chemistry.

[26]  C. Nunes,et al.  Biophysics in cancer: The relevance of drug-membrane interaction studies. , 2016, Biochimica et biophysica acta.

[27]  N. Barnes,et al.  Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. , 1997, Thorax.

[28]  R. Krell,et al.  Synthesis and pharmacological characterization of a series of leukotriene analogues with antagonist and agonist activities. , 1988, Journal of medicinal chemistry.

[29]  Tomohiko Yamaguchi,et al.  Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening. , 2015, Bioorganic & medicinal chemistry.

[30]  M. Toda,et al.  New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships. , 1988, Journal of medicinal chemistry.

[31]  G. Schneider,et al.  Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. , 2010, Journal of medicinal chemistry.

[32]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[33]  S. Laufer Discovery and development of ML3000 , 2001, InflammoPharmacology.

[34]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[35]  G. Schneider,et al.  Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. , 2014, Journal of medicinal chemistry.

[36]  B D Hammock,et al.  Rationally designed multitarget agents against inflammation and pain. , 2013, Current medicinal chemistry.

[37]  A. Paradiso,et al.  Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. , 2012, Journal of medicinal chemistry.

[38]  Isabelle Krimm,et al.  Ligand specificity, privileged substructures and protein druggability from fragment-based screening. , 2011, Current opinion in chemical biology.

[39]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[40]  B. Persson,et al.  Common structural features of mapeg—a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism , 2008, Protein science : a publication of the Protein Society.

[41]  O. Hucke,et al.  Development of Specific “Drug‐Like Property” Rules for Carboxylate‐Containing Oral Drug Candidates , 2010, ChemMedChem.

[42]  Eliezer J Barreiro,et al.  Privileged structures: a useful concept for the rational design of new lead drug candidates. , 2007, Mini reviews in medicinal chemistry.

[43]  A. Sala,et al.  Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT₂ receptor. , 2015, Prostaglandins & other lipid mediators.

[44]  D. Greaves,et al.  Synthetic chemerin-derived peptides suppress inflammation through ChemR23 , 2008, The Journal of experimental medicine.

[45]  Carlo Ballatore,et al.  Carboxylic Acid (Bio)Isosteres in Drug Design , 2013, ChemMedChem.

[46]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[47]  Jilly F. Evans,et al.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7 , 2014, British journal of pharmacology.

[48]  Andriy Kovalenko,et al.  Calculation of local water densities in biological systems: a comparison of molecular dynamics simulations and the 3D-RISM-KH molecular theory of solvation. , 2011, The journal of physical chemistry. B.

[49]  Hoa Le,et al.  Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop. , 2011, Combinatorial chemistry & high throughput screening.

[50]  H. Aishita,et al.  In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. , 1992, Japanese journal of pharmacology.

[51]  N. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[52]  O. Civelli,et al.  Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. , 2000, Molecular pharmacology.

[53]  A. Ichimura,et al.  Nutritional Signaling via Free Fatty Acid Receptors , 2016, International journal of molecular sciences.

[54]  L. Roncucci,et al.  Chemerin/chemR23 axis in inflammation onset and resolution , 2014, Inflammation Research.

[55]  G. Thatcher,et al.  Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE. , 2017, Current topics in medicinal chemistry.

[56]  D. Bernlohr,et al.  Fatty acid binding proteins stabilize leukotriene A4: competition with arachidonic acid but not other lipoxygenase products. , 2004, Journal of lipid research.

[57]  J. Evans,et al.  Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. , 1995, Canadian journal of physiology and pharmacology.

[58]  E. Barreiro,et al.  From nature to drug discovery: the indole scaffold as a 'privileged structure'. , 2009, Mini reviews in medicinal chemistry.

[59]  R. Krell,et al.  A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. , 1990, Journal of medicinal chemistry.

[60]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[61]  C. Koboldt,et al.  N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.

[62]  Jingwei Shao,et al.  Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. , 2014, Drug discovery today.

[63]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[64]  M. Schubert-Zsilavecz,et al.  Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα. , 2014, Bioorganic & medicinal chemistry letters.

[65]  M. Schubert-Zsilavecz,et al.  Novel prostaglandin receptor modulators: a patent review (2002 – 2012) – part I: non-EP receptor modulators , 2013, Expert opinion on therapeutic patents.

[66]  Yanping Xu Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases. , 2016, Journal of medicinal chemistry.

[67]  R. Murphy,et al.  Biosynthesis and metabolism of leukotrienes. , 2007, The Biochemical journal.

[68]  P. Jakobsson,et al.  Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation. , 2013, Prostaglandins & other lipid mediators.

[69]  C. Serhan,et al.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.

[70]  Paul D. Jones,et al.  1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. , 2011, Bioorganic & medicinal chemistry letters.

[71]  Y. Yu,et al.  Fragment-based discovery of novel and selective mPGES-1 inhibitors Part 1: identification of sulfonamido-1,2,3-triazole-4,5-dicarboxylic acid. , 2013, Bioorganic & medicinal chemistry letters.

[72]  J. Peters Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.

[73]  Jilly F. Evans,et al.  Characterization of the human cysteinyl leukotriene CysLT1 receptor , 1999, Nature.

[74]  J. Chambers,et al.  Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. , 1999, Molecular pharmacology.

[75]  O. Werz,et al.  Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. , 2008, Journal of medicinal chemistry.

[76]  D. A. Walsh,et al.  Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. , 1984, Journal of medicinal chemistry.

[77]  M. Furuhashi,et al.  Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets , 2008, Nature Reviews Drug Discovery.

[78]  J. A. Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[79]  Daniela Schuster,et al.  Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening , 2014, J. Chem. Inf. Model..

[80]  H. Edelsbrunner,et al.  Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design , 1998, Protein science : a publication of the Protein Society.

[81]  P. Young,et al.  The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. , 1992, International journal of immunopharmacology.

[82]  A. Stalder,et al.  Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949 , 2017, British journal of clinical pharmacology.

[83]  D. Serra,et al.  Fatty acid metabolism and the basis of brown adipose tissue function , 2015, Adipocyte.

[84]  J. Crowet,et al.  Complementary biophysical tools to investigate lipid specificity in the interaction between bioactive molecules and the plasma membrane: A review. , 2014, Biochimica et biophysica acta.

[85]  F. Kuipers,et al.  Beyond intestinal soap—bile acids in metabolic control , 2014, Nature Reviews Endocrinology.

[86]  Petra Schneider,et al.  Virtual Screening for PPAR Modulators Using a Probabilistic Neural Network , 2006, ChemMedChem.

[87]  M. Romano,et al.  Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. , 2015, European journal of pharmacology.

[88]  J. Rokach,et al.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. , 2015, Biochimica et biophysica acta.

[89]  Ruili Huang,et al.  Identification of Clinically Used Drugs That Activate Pregnane X Receptors , 2011, Drug Metabolism and Disposition.

[90]  B. Levy,et al.  Lipid mediators in the resolution of inflammation. , 2015, Cold Spring Harbor perspectives in biology.

[91]  Gisbert Schneider,et al.  Shapelets: Possibilities and limitations of shape‐based virtual screening , 2008, J. Comput. Chem..

[92]  C. Andrade,et al.  QSAR and QM/MM approaches applied to drug metabolism prediction. , 2012, Mini reviews in medicinal chemistry.

[93]  M. Lehr,et al.  Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1. , 2012, European journal of medicinal chemistry.

[94]  A. Gaggar,et al.  A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation , 2010, Science.

[95]  Christian Wolfrum,et al.  Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors α- and γ-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Chang-Guo Zhan,et al.  Novel human mPGES-1 inhibitors identified through structure-based virtual screening. , 2011, Bioorganic & medicinal chemistry.

[97]  Fung Wp,et al.  Effects of some naturally occurring prostaglandins and synthetic analogues on gastric secretion and ulcer healing in man. , 1976 .

[98]  W Patrick Walters,et al.  Acidic and basic drugs in medicinal chemistry: a perspective. , 2014, Journal of medicinal chemistry.

[99]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[100]  Camille G Wermuth,et al.  Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.

[101]  R. Krell,et al.  Biochemical and Pharmacological Characterization of the Binding of the Selective Peptide‐Leukotriene Antagonist, 3H‐ICI 198,615, to Leukotriene D4 Receptors in Guinea‐Pig Lung Membranes , 1988, Annals of the New York Academy of Sciences.

[102]  J C Sacchettini,et al.  Crystal structure of rat intestinal fatty-acid-binding protein. Refinement and analysis of the Escherichia coli-derived protein with bound palmitate. , 1989, Journal of molecular biology.

[103]  A. A. Santilli,et al.  A potent antihypercholesterolemic agent: [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643) , 1974, Experientia.

[104]  Dennis A. Smith Metabolism, pharmacokinetics and toxicity of functional groups : impact of chemical building blocks on ADMET , 2010 .

[105]  Xiaofeng Cui,et al.  Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics. , 2013, Current medicinal chemistry.

[106]  J B Farmer,et al.  Selective inhibitor of slow reacting substance of anaphylaxis. , 1973, Nature: New biology.

[107]  Karl Edman,et al.  Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.

[108]  S. Wright,et al.  Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. , 2004, DNA and cell biology.

[109]  Petra Schneider,et al.  Scaffold‐Hopping Cascade Yields Potent Inhibitors of 5‐Lipoxygenase , 2008, ChemMedChem.

[110]  J. Yanni,et al.  Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy , 2000, Inflammation.

[111]  J. Wielens,et al.  The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein* , 2005, Journal of Biological Chemistry.

[112]  A. Lavecchia,et al.  New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression. , 2013, Journal of medicinal chemistry.

[113]  G. Keserű,et al.  Is there a link between selectivity and binding thermodynamics profiles? , 2015, Drug discovery today.

[114]  N. Meanwell Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[115]  M. Schubert-Zsilavecz,et al.  Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands. , 2015, Bioorganic & medicinal chemistry.

[116]  J. Gordon,et al.  Refined apoprotein structure of rat intestinal fatty acid binding protein produced in Escherichia coli. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Björn Krüger,et al.  The holistic integration of virtual screening in drug discovery. , 2013, Drug discovery today.

[118]  Lucia Altucci,et al.  Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.

[119]  Daniel M. Lowe,et al.  ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. , 2009, Bioorganic & medicinal chemistry.

[120]  Petra Schneider,et al.  Revealing the macromolecular targets of complex natural products. , 2014, Nature chemistry.

[121]  Thierry Langer,et al.  Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. , 2008, Journal of medicinal chemistry.

[122]  H. Tsuchiya Membrane Interactions of Phytochemicals as Their Molecular Mechanism Applicable to the Discovery of Drug Leads from Plants , 2015, Molecules.

[123]  K. Seong,et al.  Psoralidin, a dual inhibitor of COX‐2 and 5‐LOX, regulates ionizing radiation (IR)‐induced pulmonary inflammation , 2011, Biochemical pharmacology.

[124]  B. Gertz,et al.  Pharmacokinetics, Bioavailability, and Safety of Montelukast Sodium (MK-0476) in Healthy Males and Females , 1996, Pharmaceutical Research.

[125]  A. Holt,et al.  On the disruption of biochemical and biological assays by chemicals leaching from disposable laboratory plasticware. , 2012, Canadian journal of physiology and pharmacology.

[126]  J Zhang,et al.  Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. , 1996, The Journal of allergy and clinical immunology.

[127]  M. Lambert,et al.  Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. , 2007, Journal of medicinal chemistry.

[128]  G. Schneider,et al.  The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5‐lipoxygenase products , 2007, British journal of pharmacology.

[129]  B. Staels,et al.  Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[130]  A. D. de Lera,et al.  An Endogenous Mammalian Retinoid X Receptor Ligand, At Last! , 2016, ChemMedChem.

[131]  Daniel Moser,et al.  Exploring the chemical space of multitarget ligands using aligned self-organizing maps. , 2013, ACS medicinal chemistry letters.

[132]  R. Young,et al.  The discovery of a new structural class of potent orally active leukotriene D4 antagonists , 1992 .

[133]  Susanne Winiwarter,et al.  Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases. , 2015, Journal of medicinal chemistry.

[134]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[135]  S. Majumdar,et al.  Role of metabolism in ocular drug delivery. , 2004, Current drug metabolism.

[136]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[137]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[138]  C. Serhan,et al.  Resolvins and protectins in inflammation resolution. , 2011, Chemical reviews.

[139]  A. Robert,et al.  Inhibition of gastric secretion by prostaglandins , 1967, The American journal of digestive diseases.

[140]  O. Werz,et al.  Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions. , 2016, Journal of medicinal chemistry.

[141]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[142]  M. Schubert-Zsilavecz,et al.  Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012) , 2013, Expert opinion on therapeutic patents.

[143]  Charles N. Serhan,et al.  Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.

[144]  Hilde Cheroutre,et al.  Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the Immune System. , 2016, Annual review of immunology.

[145]  Jilly F. Evans,et al.  5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. , 2011, Journal of medicinal chemistry.

[146]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[147]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[148]  D. Steinhilber,et al.  Recent advances in the search for novel 5-lipoxygenase inhibitors. , 2014, Basic & clinical pharmacology & toxicology.

[149]  K. Takano,et al.  Estrogenic impurities in labware , 2001, Nature Biotechnology.

[150]  R. Young,et al.  Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction , 1995 .

[151]  Ying Yu,et al.  Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists. , 2012, Journal of medicinal chemistry.

[152]  Chris Oostenbrink,et al.  Prediction of cytochrome P450 mediated metabolism. , 2015, Advanced drug delivery reviews.

[153]  Y. Uto,et al.  Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors. , 2016, Chemistry and physics of lipids.

[154]  C. Johansson,et al.  Stimulation by intragastrically administered E2 prostaglandins of human gastric mucus output , 1979, European journal of clinical investigation.

[155]  R. Parker,et al.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.

[156]  G. Bifulco,et al.  Structure‐Based Design of Microsomal Prostaglandin E2 Synthase‐1 (mPGES‐1) Inhibitors using a Virtual Fragment Growing Optimization Scheme , 2016, ChemMedChem.

[157]  R. Keith,et al.  In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. , 1987, The Journal of pharmacology and experimental therapeutics.

[158]  Brian Pease,et al.  Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography† , 2009, Journal of medicinal chemistry.

[159]  Gregor Eichele,et al.  International Union of Pharmacology. LXIII. Retinoid X Receptors , 2006, Pharmacological Reviews.

[160]  R. Desimone,et al.  Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.

[161]  Jilly F. Evans,et al.  International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions , 2011, Pharmacological Reviews.

[162]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[163]  James Ferguson,et al.  Software automation tools for increased throughput metabolic soft-spot identification in early drug discovery. , 2013, Bioanalysis.

[164]  Dieter Lang,et al.  Predicting drug metabolism: experiment and/or computation? , 2015, Nature Reviews Drug Discovery.

[165]  R. Obach,et al.  Physicochemical determinants of human renal clearance. , 2009, Journal of medicinal chemistry.

[166]  Tudor I. Oprea,et al.  The significance of acid/base properties in drug discovery. , 2013, Chemical Society reviews.

[167]  J. Bassaganya-Riera,et al.  Virtual Screening as a Technique for PPAR Modulator Discovery , 2009, PPAR research.

[168]  James R Kiefer,et al.  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. , 2010, Bioorganic & medicinal chemistry letters.

[169]  Leandro Martínez,et al.  Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists , 2012, PloS one.

[170]  D. Merk Chances and challenges of retinoid X receptor gamma targeting for regenerative multiple sclerosis treatment. , 2015, Future medicinal chemistry.

[171]  Gerhard Klebe,et al.  Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.

[172]  A. Harris,et al.  Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4 , 2016, Oncogene.

[173]  Daniel Moser,et al.  Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering. , 2012, ACS medicinal chemistry letters.

[174]  L. Bito,et al.  Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. , 1993, Journal of medicinal chemistry.

[175]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[176]  R. Murphy,et al.  Leukotriene C: a slow-reacting substance from murine mastocytoma cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[177]  Brian K Shoichet,et al.  A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.

[178]  Y. Urade,et al.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. , 2011, Chemical reviews.

[179]  R Scott Obach,et al.  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. , 2010, Journal of medicinal chemistry.

[180]  Bengt Samuelsson,et al.  Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor , 2014, Proceedings of the National Academy of Sciences.

[181]  T. Maduskuie,et al.  Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes. , 1989, Journal of Medicinal Chemistry.

[182]  T. Velkov Thermodynamics of lipophilic drug binding to intestinal fatty acid binding protein and permeation across membranes. , 2009, Molecular pharmaceutics.

[183]  D. Brocks,et al.  Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers. , 2003, British Journal of Clinical Pharmacology.

[184]  O. Werz,et al.  Pirinixic acids: flexible fatty acid mimetics with various biological activities. , 2015, Future medicinal chemistry.

[185]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[186]  Weihua Li,et al.  Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking. , 2012, Bioorganic & medicinal chemistry letters.

[187]  Kazuya Maeda,et al.  Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.

[188]  T. Hori,et al.  Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy. , 2006, Journal of biochemistry.

[189]  Manfred Schubert-Zsilavecz,et al.  Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. , 2012, Future medicinal chemistry.

[190]  S. Narumiya,et al.  International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress , 2011, Pharmacological Reviews.

[191]  M. Schubert-Zsilavecz,et al.  Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present) , 2012, Expert opinion on therapeutic patents.

[192]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[193]  Sanjay S. Patel,et al.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. , 1996, Drugs & aging.

[194]  Thomas Mendgen,et al.  Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[195]  E. Freire Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.

[196]  G. Schneider,et al.  Revealing the Macromolecular Targets of Fragment-Like Natural Products. , 2015, Angewandte Chemie.

[197]  Wolfgang Albrecht,et al.  Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[198]  A. Wolkoff Organic anion uptake by hepatocytes. , 2014, Comprehensive Physiology.

[199]  Sridhar Duvvuri,et al.  Drug delivery to the retina: challenges and opportunities , 2003, Expert opinion on biological therapy.

[200]  Bernard Faller,et al.  Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. , 2009, Journal of medicinal chemistry.

[201]  I. Lu,et al.  Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.

[202]  M. Dawson,et al.  The retinoid X receptors and their ligands. , 2012, Biochimica et biophysica acta.

[203]  D. Steinhilber,et al.  Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. , 2014, Basic & clinical pharmacology & toxicology.

[204]  K. Maeda Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. , 2015, Biological & pharmaceutical bulletin.

[205]  Dora M Schnur,et al.  Are target-family-privileged substructures truly privileged? , 2006, Journal of medicinal chemistry.

[206]  Jan M. Kriegl,et al.  From Molecular Shape to Potent Bioactive Agents I: Bioisosteric Replacement of Molecular Fragments , 2009, ChemMedChem.

[207]  A. Brash,et al.  The Structure of Human 5-Lipoxygenase , 2011, Science.

[208]  Simona Distinto,et al.  How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..

[209]  M. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[210]  Takao Shimizu,et al.  The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo , 2006, Pharmacological Reviews.

[211]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[212]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[213]  S. Hwang,et al.  Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo , 2009, Molecular Cancer Therapeutics.

[214]  Bernstein Chemistry and structure-activity relationships of leukotriene receptor antagonists , 1998, American journal of respiratory and critical care medicine.

[215]  G. Schneider,et al.  From Molecular Shape to Potent Bioactive Agents II: Fragment‐Based de novo Design , 2009, ChemMedChem.

[216]  D. Steinhilber,et al.  Small molecules with anti-inflammatory properties in clinical development. , 2016, Pharmacology & therapeutics.

[217]  Joseph Cheriyan,et al.  Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. , 2016, British journal of clinical pharmacology.

[218]  J. D. Clark,et al.  Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors. , 2008, Analytical biochemistry.

[219]  A. K. Willard,et al.  Chemically stable homocinnamyl analogues of the leukotrienes: synthesis and preliminary biological evaluation. , 1986, Journal of medicinal chemistry.

[220]  D. Steinhilber,et al.  Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity. , 2013, Biochemical pharmacology.

[221]  B. Hudson,et al.  Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes , 2013, ACS medicinal chemistry letters.

[222]  E. Barreiro,et al.  The methylation effect in medicinal chemistry. , 2011, Chemical reviews.

[223]  R. Thandavarayan,et al.  Targeting fatty acid metabolism in heart failure: is it a suitable therapeutic approach? , 2016, Drug discovery today.

[224]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[225]  A. Brash,et al.  Conversion of human 5‐lipoxygenase to a 15‐lipoxygenase by a point mutation to mimic phosphorylation at Serine‐663 , 2012 .

[226]  A. Kay,et al.  Inhibition of eosinophil chemotaxis by the antagonist of slow reacting substance of anaphylaxis—compound FPL 55712 * , 1974, The Journal of pharmacy and pharmacology.

[227]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[228]  Daniela Schuster,et al.  Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation , 2011, Bioorganic & medicinal chemistry.

[229]  D. A. Walsh,et al.  Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid. , 1990, Journal of medicinal chemistry.

[230]  Tomohiko Yamaguchi,et al.  Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography. , 2014, Bioorganic & medicinal chemistry.

[231]  F. Hart,et al.  Indomethacin: A New Non-steroid Anti-inflammatory Agent , 1963, British medical journal.

[232]  Richard Morphy,et al.  The physicochemical challenges of designing multiple ligands. , 2006, Journal of medicinal chemistry.

[233]  R. Glazer,et al.  Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation , 2010, PPAR research.

[234]  Wenlian Zhang,et al.  Identification of the Orphan G Protein-coupled Receptor GPR31 as a Receptor for 12-(S)-Hydroxyeicosatetraenoic Acid* , 2011, The Journal of Biological Chemistry.